Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Amgen |
---|---|
Information provided by: | Amgen |
ClinicalTrials.gov Identifier: | NCT00042432 |
This study will assess an investigational medication for patients with chronic renal insufficiency (pre-dialysis) who have secondary hyperparathyroidism.
Condition | Intervention | Phase |
---|---|---|
Secondary Hyperparathyroidism Chronic Renal Insufficiency |
Drug: AMG 073 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Responsible Party: | Amgen Inc. ( Global Development Leader ) |
Study ID Numbers: | 20010239 |
Study First Received: | July 29, 2002 |
Last Updated: | December 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00042432 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Parathyroid Diseases Hyperparathyroidism, Secondary Renal Insufficiency Urologic Diseases Hyperparathyroidism |
Renal Insufficiency, Chronic Neoplasm Metastasis Endocrine System Diseases Endocrinopathy Kidney Diseases |
Parathyroid Diseases Neoplasms Neoplastic Processes Renal Insufficiency Hyperparathyroidism, Secondary Pathologic Processes |
Urologic Diseases Hyperparathyroidism Renal Insufficiency, Chronic Neoplasm Metastasis Endocrine System Diseases Kidney Diseases |